Thalia Therapeutics plc
THAT · AIM · Health Care · mcap £11m · 0.6p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 30 Sep 26 | Results | Half-year Results
Strategic transformation establishes Thalia as a clinical-stage RNA therapeutics company with a diversified development pipeline |
+0.0% |
| 29 Sep 26 | New Patent Granted for miRisten in China
Extends intellectual property protection for Thalia’s clinical-stage AML programme |
+4.2% | |
| 25 Sep 26 | RNA gene-silencing cardiovascular program advances
Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces it has completed the in |
+4.3% | |
| 15 Sep 26 | Business Update and Notice of Results
Progress across clinical-stage oncology, cardiovascular and RNA delivery programmes |
+4.5% | |
| 23 Jul 26 | Grant of Director Share Options
Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces that it has granted opt |
+0.0% | |
| 17 Jul 26 | AGM Statement
Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, will hold its Annual General Meeting ("AGM") tod |
+0.0% | |
| 24 Jun 26 | Fundraise | Acquisition and £2.75 million Fundraise
Acquisition of oncology company Sanmirna Therapeutics Inc for its clinical-stage Acute Myeloid Leukaemia RNA therapy |
+17.4% |
| 23 Jun 26 | Results | Final Results
Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA-based therapeutics, in both oncology and cardiovascular disease, as well as broadly applicable delivery technologies, today announces |
+0.0% |
| 09 Jun 26 | New article: RNA medicine enters its second act
New article: RNA medicine enters its second act |
+0.0% | |
| 02 Jun 26 | Board change | CEO Interview
CEO Interview: Building a Differentiated RNA Therapeutics Company |
+0.0% |
| 13 May 26 | Board change | CEO Interview: Thalia’s RNA Therapeutics Strategy
Thalia Therapeutics plc (AIM: THAT), a biotech company developing innovative RNA therapeutics, is pleased to announce the release of a new video interview with Chief Executive Officer, Dr David Solomon. |
+0.0% |
| 20 Apr 26 | Change of Registered Address
Thalia Therapeutics plc (AIM: THAT), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, announces that it has changed its registered address |
+0.0% | |
| 27 Feb 26 | Notice of GM and Proposed Change of Name
Notice of General Meeting and Proposed Change of Name to Thalia Therapeutics plc |
+9.1% | |
| 24 Feb 26 | Board change | CEO Appointment & Name Change Thalia Therapeutics
CEO Appointment, Strategic Update and Name Change to Thalia Therapeutics |
+4.8% |
| 17 Dec 25 | Business and Operational Update
N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to provide an operational update and business review |
+0.0% |
Company filings. Not investment advice.